Supporting & empowering the journey to wellness.


Special Access for psilocybin & MDMA

Pending approval of regulatory change, Auvega Labs Inc. intends to support practitioners in helping their patients obtain Special Access to psychedelic-assisted therapies for a range of conditions and delivering these through the clinics.

Health Canada has posted its Notice of Intent, subject to public consultation, to revise its Special Access Programme to allow legal access to psilocybin and MDMA outside of clinical trials, while the substances await formal approvals.

Auvega Labs Inc. supports Health Canada’s leadership and stands in solidarity with the individuals and organizations who have advocated to increase safe and evidence-based accessibility. By working together and supporting evidence-based approaches to mental health, psychedelic-assisted psychotherapy can become a routine part of the healthcare system.